Klein Lawrence Otto reported option exercise involving 25,000 derivative units of Oruka Therapeutics, Inc. at $0.00 for $0 on Oct 1, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Executive Officer
Chief Executive Officer
Filed Oct 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
25,000Employee Warrant (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
1,528,513Direct
Trade date
Oct 1, 2026Option exercise
Filed
Oct 2, 2026, 7:54 PM ET1-day reporting delay
Accession
0000907654-26-000104Code M · Transaction 236048
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Oct 1, 2026Sell16,246$83.40−$1,354,882.28Trade 236045
Oct 1, 2026Sell8,554$84.03−$718,754.98Trade 236046
Oct 1, 2026Sell200$84.78−$16,956Trade 236047
Oct 1, 2026Option exercise25,000$7.80$195,000Trade 236044
5 transaction rows in this filing. Joint filers share the same rows.

ORKA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ORKA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +9%1w ago +1.1%1d ago −1.5%
Returns since7d −2.9%30d +15%90d180d1y

Footnotes in full

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive. F5: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.